Shares of CRISPR Therapeutics (CRSP) have lost more than 30% in the past year. Though the stock soared at the onset of 2024, thanks to the FDA approval of its one-shot gene therapy Casgevy for two blood disorders, much of these gains have pared mainly due to the waning interest of investors in CRSP.Despite securing the first product approval in Casgevy, the company is yet to record revenues from its sales. Also, a lack of pipeline updates beyond Casgevy’s approval is not sitting well with the investors.Anot ...

投资理念与策略 - 核心投资理念是价值投资 倾向于以合理价格购买优质企业 并长期持有 [1] - 投资风格受巴菲特和芒格影响 但保持开放态度 接受其他投资理念 [1] - 投资决策基于深入研究 包括财务指标分析 行业研究 公司新闻跟踪等 [1] - 投资组合管理策略是长期持有 尽量减少买卖操作 并将股息再投资 [1] 行业经验 - 曾在航空航天和美容行业担任CFO 管理过销售额在5000万至1亿美元之间的公司 [1] - 拥有超过20年的CPA经验 曾在四大会计师事务所担任高级经理 [1] 投资方法 - 投资前和投资期间都会进行深入研究 包括季度财务检查 电话会议跟踪 新闻监测等 [1] - 注重多角度分析 不仅关注正面因素 也重视潜在风险 [1]

关键要点总结 涉及的行业或公司 - 公司：CRISPR Therapeutics AG (NASDAQ:CRSP) [1] - 行业：生物技术、基因编辑、医药 [4] 核心观点和论据 - 公司已有一款获批疗法CASGEVY，基于诺贝尔奖获奖技术CRISPR/Cas9 [4] - 公司有五个临床项目，涵盖肿瘤学、自身免疫、心血管药物和罕见疾病 [5] - 公司还有十个临床前项目，显示出强大的研发潜力 [5] - 业务分为四个主要领域，其中血红蛋白病（heme）是核心领域之一 [5] - CASGEVY是与Vertex合作开发的药物，用于治疗镰状细胞病 [6] 其他重要内容 - 公司CEO Samarth Kulkarni在JPMorgan Healthcare会议上发表演讲，展望未来 [3] - 演讲内容包括公司过去十年的成就和未来展望 [3] - 公司提醒投资者注意前瞻性声明，并建议访问公司网站查看风险因素 [4] 引用 - [1][2][3][4][5][6]

If you're an investor searching for the next big market winners, Wall Street analysts have zeroed in on one biotech stock that could deliver huge gains in a defined time frame.Citing positive developments in its development programs, analysts from a couple of investment banks think CRISPR Therapeutics (CRSP -2.12%) could more than double your money in the year ahead.But before committing any amount of your own money to this stock, it's important to remember the analysts who recommended it have very little t ...

-Ongoing launch of CASGEVY® continues to gain momentum- -2025 is poised to be a catalyst-rich year with key updates across several programs- -Starting 2025 with a strong balance sheet with approximately $1.9 billion in cash, cash equivalents, and marketable securities- ZUG, Switzerland and BOSTON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today highlighted its strategic prior ...

Some of the best possible returns for investors come by not going after megacaps, but instead pursuing stocks that have more modest valuations. Mid-cap stocks represent companies valued at between $2 billion and $10 billion. If they give investors a reason to be bullish on their growth prospects or show that they're on the right path, these types of investments can double in value and be 10-baggers in the long run.To be clear, it doesn't always work out that way, and there are risks with these types of stoc ...

ZUG, Switzerland and BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 2:15 p.m. PT in San Francisco. A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of ...

分析师背景 - 分析师拥有生物学背景 生物医学硕士和生物工程博士学位 并在细胞和基因疗法(CGT)领域有超过20年的研发经验 专注于解决骨科和罕见疾病等临床需求 [3] - 分析师利用生命科学背景评估新型治疗方法的潜力 包括使用CGT的治疗方法 以及这些方法为股东带来回报的能力 [3] - 分析师专注于分析生物技术 制药 医疗技术和医疗保健行业的股票 提供对公司的见解 [3] 分析师关联 - 分析师与另一位Seeking Alpha贡献者"Euro Invest"有关联 但各自独立工作 并遵守Seeking Alpha的共享关联指南 [3] 分析师披露 - 分析师在文章中提到的公司中没有股票 期权或类似衍生品头寸 也没有计划在未来72小时内启动任何此类头寸 [2] - 分析师未因撰写文章而获得任何补偿(除了来自Seeking Alpha的补偿) 并且与文章中提到的任何公司没有业务关系 [2]

Genomics companies analyze and interpret genetic information to uncover insights about genetic variations and disease mechanisms and develop tests, therapies and technologies to advance personalized medicine. Companies in synthetic biology, engineer biological systems for practical applications, including pharmaceuticals and agriculture, using genetic engineering and biotechnology techniques to design novel organisms and processes. The promise of curing genetic diseases and extending human lifespan position ...

What's going on with CRISPR Therapeutics (CRSP 0.83%)? The company's shares have been southbound for the better part of three years. And despite major regulatory wins since late 2023, the biotech hasn't recovered: The stock is down 23% year to date.Can CRISPR Therapeutics bounce back? Some recent developments could move the needle for the gene-editing specialist down the road. Let's find out what they are and what they mean for investors.Expanded coverage for CRISPR Therapeutics' crown jewelSince November 2 ...